title: Improvement of dissolution behavior of poorly water soluble drugs by biodegradable polymeric submicron carriers containing sparingly methylated β-cyclodextrin.
abstract: The objective of this study was to develop submicron carriers of two drugs that are practically insoluble in water, i.e. meloxicam and aceclofenac, to improve their dissolution behavior. The phase solubility of the drugs was studied using different concentrations of sparingly methylated β-cyclodextrin, Kleptose(®) Crysmeβ (Crysmeb), in the presence and absence of 0.2 % w/v water-soluble chitosan. Drug-loaded submicron particles (SMPs) were prepared using chitosan chlorhydrate and Crysmeb by the ionotropic gelation method. The SMPs were characterized in terms of powder X-ray diffraction, Fourier transforms infrared spectroscopy, size determination, process yield, drug loading, encapsulation efficiency, surface morphology and in vitro release. The drug loading in the SMPs was enhanced in the presence of Crysmeb. The in vitro drug release was found to be enhanced with SMPs prepared using higher concentrations of Crysmeb. These results indicate that SMPs formed from chitosan chlorhydrate and Crysmeb are promising submicron carriers for enhancing the dissolution of meloxicam and aceclofenac.
authors: Institute of Pharmaceutical Education and Research, Borgaon (Meghe), Wardha, Maharashtra, India. dileshsinghavi@rediffmail.com
authors: Dilesh J
authors: DJ
authors: Singhavi
authors: Shagufta
authors: S
authors: Khan
authors: Pramod G
authors: PG
authors: Yeole
mesh_terms: D001672:Biocompatible Materials; D008745:Methylation; D004364:Pharmaceutical Preparations / Q000737:chemistry*; D011108:Polymers / Q000737:chemistry*; D033362:Powder Diffraction; D012995:Solubility; D014867:Water / Q000737:chemistry*; D047392:beta-Cyclodextrins / Q000737:chemistry*
chemical_list: D001672:Biocompatible Materials; D004364:Pharmaceutical Preparations; D011108:Polymers; D047392:beta-Cyclodextrins; D014867:Water
references: J Aerosol Med. 2004 Summer;17(2):174-85
references: 15294069
references: Skin Pharmacol Physiol. 2006;19(4):190-7
references: 16679821
references: Curr Nanosci. 2005 Nov 1;1(3):237-243
references: 19865587
references: Drug Dev Ind Pharm. 2000 Aug;26(8):857-66
references: 10900542
references: AAPS PharmSciTech. 2008;9(4):1102-9
references: 18975116
references: Int J Pharm. 2003 Jan 2;250(1):215-26
references: 12480287
references: Drug Dev Ind Pharm. 2006 Nov-Dec;32(10):1123-34
references: 17090434
references: J Control Release. 2001 Jun 15;73(2-3):137-72
references: 11516494
references: Pharmazie. 2006 Apr;61(4):306-11
references: 16649543
references: Eur J Pharm Biopharm. 2007 Apr;66(1):73-82
references: 17056238
references: Biomaterials. 2005 May;26(14):2089-94
references: 15576183
references: J Pharm Pharmacol. 2009 Dec;61(12):1609-16
references: 19958582
references: J Pharm Pharmacol. 2007 Nov;59(11):1501-7
references: 17976260
references: Int J Pharm. 2006 Aug 17;319(1-2):130-8
references: 16713152
references: Eur J Pharm Biopharm. 2004 Jan;57(1):35-52
references: 14729079
references: Pharm Res. 2007 Dec;24(12):2223-30
references: 17828445
references: Pak J Pharm Sci. 2011 Oct;24(4):533-8
references: 21959817
references: J Pharm Sci. 1991 Dec;80(12):1162-70
references: 1815076
references: J Control Release. 2009 Jun 5;136(2):110-6
references: 19331849
references: Pharm Sci Technol Today. 2000 Jun;3(6):198-204
references: 10840390
references: Eur J Pharm Biopharm. 2006 Jun;63(2):79-86
references: 16527473
references: Curr Drug Deliv. 2011 Jul;8(4):330-45
references: 21453264
references: J Control Release. 2001 Jun 15;73(2-3):255-67
references: 11516503
references: Int J Pharm. 2009 Jun 22;375(1-2):97-106
references: 19481695
references: Expert Opin Drug Deliv. 2009 Sep;6(9):923-39
references: 19637983
references: Pharm Res. 1994 Oct;11(10):1379-84
references: 7855038
references: Chem Commun (Camb). 2010 Aug 21;46(31):5622-33
references: 20585706